How to Buy Biohaven Stock
Biohaven Ltd
Biohaven is a biotech company located in Connecticut, United States, which is part of the Healthcare sector, and is traded under the ticker BHVN on the NYSE exchange.
Biohaven stock last closed at $39.90, down 0.7% from the previous day, and has increased 202.27% in one year. It has overperformed other stocks in the Biotechnology industry by 2.21 percentage points. Biohaven stock is currently +206.22% from its 52-week low of $13.03, and -35.86% from its 52-week high of $62.21.
At the moment, there are 81.58M BHVN shares outstanding. The market capitalization of BHVN is $3.26B. In the last 24 hours, 794,513 BHVN shares were traded.
How to Buy Biohaven Stock
Not sure how to invest in Biohaven stock? Here's how.
- Decide where to buy Biohaven stock: You need to pick an online brokerage, but don't worry - we've researched dozens of online brokerages and apps to help you determine where to buy Biohaven stock.
- Open a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Put funds into your brokerage account: Choose your method of payment and add your information.
- Analyze Biohaven stock: The Biohaven ticker symbol is BHVN. Is Biohaven stock a good investment? Should you buy shares of BHVN? How do BHVN's underlying business fundamentals look? Do top analysts think Biohaven is a good buy? Why has BHVN's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if BHVN is a good stock to buy).
- Make your BHVN purchase: Decide if you will purchase BHVN shares at the current market price or use a limit order to buy BHVN shares at a given price.
- Get key alerts regarding your BHVN position: Create a watchlist to get live updates on your new investment in Biohaven stock.
Step 1: Decide where to buy Biohaven stock
You need an online brokerage account to access the NYSE market and buy BHVN stock.
Our favorite brokerage: eToro
In our opinion, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with zero commissions: Invest without commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still buy the stock.
- Access to global markets: From Technology to Financial Services, New York to Hong Kong — you can fill your portfolio with stocks from the world's leading stock exchanges.
- Social investing: eToro boasts a community with more than 20 million users worldwide. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by creating an account with eToro now.
Open eToro AccountStep 2: Open a brokerage account
Now that you've chosen your brokerage, the next step is to fill out some personal details so you can buy BHVN today.
How to Create a New Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Input your personal data to open a new trading account.
- Send your application by pressing the "Create Account" button. Get started with eToro today
Step 3: Put funds into your brokerage account
Now that you've finished signing up on a investment app, you need to deposit funds:
Watch the tutorial below to see the process of transferring funds into your new investment account.
Step 4: Analyze Biohaven stock
After you have decided on the best place to buy Biohaven stock, it's absolutely critical to evaluate their stock before you buy, so you can wrap your head around the risk as well as the opportunity.
Biohaven shares data
Biohaven Zen Score
WallStreetZen was created to help part-time investors do more in-depth fundamental analysis in minutes instead of hours.
You can see all of the due diligence checks on BHVN's stock page.
Is BHVN stock overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge BHVN's fair value.
Using relative valuations methods:
- BHVN could be overvalued based on its P/B ratio of 7.61x, relative to Biotechnology industry P/B ratio of 5.99x
You can access additional valuation research on BHVN's stock here.
Is BHVN a healthy company?
Positive Financial Indicators:
- BHVN has a low debt to equity ratio of 0.2.
- There are more short-term assets than long-term liabilities on the BHVN balance sheet.
- BHVN has cash burn of 334773000. It has enough cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the BHVN balance sheet.
Negative Financial Indicators:
- BHVN has $381.82M in cash and short term investments. This is not enough to cover its annual cash burn of $334.77M.
Is it a good time to buy Biohaven stock, according to Wall Street analysts?
Out of 7 Equities analysts who give ratings on BHVN, the consensus analyst rating on BHVN is a Strong Buy
Please keep in mind that analyst ratings are not stock recommendations, nor are they financial advice.
Latest BHVN Analyst Upgrades/Downgrades
Brian Skorney, a top 13% analyst from Baird initiates coverage on BHVN with a buy rating and announces their BHVN price target of $58.00, on Dec 8, 2023.
Christopher Raymond, a top 12% analyst from Piper Sandler maintains BHVN with a strong buy rating and raises their BHVN price target from $29.00 to $36.00, on Nov 15, 2023.
Piper Sandler's Christopher Raymond raised their price target on Biohaven (NYSE: BHVN) by 24.1% from $29 to $36 on 2023/11/15. The analyst maintained their Strong Buy rating on the stock.
Post Biohaven's Q3 2023 earnings report, released on 2023/11/14, Raymond attributed their updated price target to "progress that continues across the company's preclinical and clinical pipelines with catalyst timing generally on track."
In terms of Biohaven's pipeline, Piper Sandler only ascribes value to BHV-7000, "which the firm believes represents a potential billion-dollar opportunity in the focal epilepsy market," the analyst noted.
Earnings Report
For Q3 2023, Biohaven reported:
- Loss per share of $1.44, down 15.2% from Q3 2022's $1.25.
- Completed public offering of 11,761,363 shares, including the exercise in full of the underwriters' option to purchase additional shares, at a price per share of $22.
- Cash and cash equivalents of $495M at quarter end, including $242M in proceeds from the public offering on 2023/10/05.
Chairman & CEO Vlad Coric, M.D. commented: "Biohaven continued to make tremendous progress in Q3, advancing multiple development programs and innovating across our entire pipeline. Most recently, we shared important data from our molecular degrader of extracellular proteins (MoDE™) program and demonstrated the potential for this technology in the field of immunology, where targeting pathologic antibodies has been shown to have important therapeutic potential.
"We have demonstrated that BHV-1300, our lead IgG degrader, has great potential with a differentiated profile. With multiple opportunities to address rare and common diseases alike, we continue to be impressed by the expansive potential of our degrader program.
"Beyond our extracellular degraders, we also shared key data from ongoing studies with BHV-7000, our highly selective Kv7.2/7.3 activator for epilepsy, mood disorders and pain.
"With the closing of our recent public offering and the achievement of several important milestones across our programs, we are in a strong position to continue to invest in accelerating and executing on our innovative pipeline
"Our unwavering patient focus and methodical scientific approach drive every layer of our decision-making, and we will progress and phase programs to balance our commitment with prudent resource allocation."
You can dive deeper into what analysts are projecting on the Biohaven stock forecast page.
BHVN Technicals
Latest Insiders Trades at BHVN
In the last 12 months, executives and large shareholders at BHVN have bought more shares than they have sold.
Gregory Bailey, Director of BHVN, was the latest BHVN insider to buy. They bought $999,156.53 worth of BHVN shares on Apr 24, 2024.
Dig into more about who owns BHVN stock here.
Does BHVN stock generate passive income?
No, Biohaven doesn't provide an income stream by paying out dividends.
What others are saying about BHVN
One of the primary reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to learn what other investors have to say.
Step 5: Make your BHVN purchase
There are two primary order types:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are mostly the easiest way to buy. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to be sure you're buying or selling at an exact price limit, use a limit order.
Click the Open Trade button and eToro will place the order.
If you need more help investing in stocks on eToro, watch the how to video below:
Step 6: Get key alerts regarding your BHVN position
Now that you own some shares in BHVN, you'll want to keep up with your investment.
Add BHVN to a watchlist to monitor your BHVN stock.
BHVN Feed
How to Buy Stock in Biohaven
To reiterate, here are the 6 steps to buy stock in Biohaven:
- Decide where to buy Biohaven stock
- Open a brokerage account
- Put funds into your brokerage account
- Analyze Biohaven stock
- Make your BHVN purchase
- Get key alerts regarding your BHVN position
If you are looking for a place to buy stocks, eToro is our recommended option.
Get Started with eToro TodayIf you want to monitor your investment in Biohaven, click below.
More "How To" Guides You May Find Useful
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.